March is Endometriosis Awareness Month, highlighting a condition that affects approximately 190 million women worldwide yet remains underdiagnosed and under-researched. Chronic pelvic pain, fatigue, infertility, and delayed diagnosis mean many patients live with symptoms for years before receiving appropriate treatment. As the clinical research community works to develop more effective therapies, rethinking clinical trial design with the patient at the center has become increasingly important.
Challenges in Endometriosis Research
Endometriosis presents several unique challenges for clinical studies, which can slow therapeutic development and limit patient participation.
- Invasive diagnostic procedures
Many trials rely on laparoscopy or tissue biopsies to confirm diagnosis or assess disease progression. These procedures can be physically demanding, costly, and may discourage potential participants from enrolling in clinical studies. - Symptom variability and subjective endpoints
Pain intensity, menstrual symptoms, and functional limitations vary significantly between individuals. This variability makes it difficult to define standardized endpoints and accurately measure treatment response across study populations. - Limited research funding
Compared with other chronic conditions, endometriosis research has historically received limited funding. This can restrict study scale, slow innovation, and limit the adoption of advanced technologies that could improve trial efficiency. - Recruitment and retention challenges
The chronic nature of the disease, combined with demanding clinical trial protocols, often makes recruitment and long-term participant retention difficult. These factors can impact study timelines and the overall quality of trial data.
Addressing these challenges requires innovative study designs that reduce patient burden while maintaining scientific rigor.
Emerging Approaches in Ongoing Clinical Trials
Several ongoing studies demonstrate how researchers are addressing these obstacles through new therapies and diagnostic approaches.
- SPIRIT 1 and 2 (Relugolix combination therapy, Phase 3)
These global trials evaluated a once-daily relugolix with estradiol and norethisterone acetate for moderate-to-severe endometriosis-associated pain. Results showed clinically meaningful reductions in both menstrual and non-menstrual pelvic pain, offering a promising non-surgical treatment option, and led to marketing approvals in the US and EU. - EMPOWER Non-Invasive Diagnostic Study
This multi-center study investigated microRNA-based blood and saliva tests as a potential alternative to diagnostic laparoscopy, with the goal of enabling earlier and less invasive diagnosis. This study led to marketing approval. - Gynica IntraVag© Phase 1 Trial
A first-in-human study exploring a non-hormonal intra-vaginal therapy platform designed to improve treatment delivery and patient tolerability. - HMI-115 Phase 3 Study
This monoclonal antibody therapy targets the prolactin receptor and has shown encouraging early results in reducing pain and improving quality of life. - Spago Nanomedical SN132D Phase 2a Trial
Researchers are evaluating an MRI contrast agent designed to enhance non-invasive imaging of endometriotic lesions, which could improve diagnostic accuracy and trial endpoint assessment.
These trials reflect broader trends in endometriosis research, including increased interest in:
- Non-invasive diagnostic tools
- Digital symptom tracking and wearable technologies
- Expanded endpoints, including quality of life, fertility outcomes, and biomarker-driven responses
Together, these innovations aim to make trials more patient-friendly while generating more meaningful clinical data.
Rethinking Clinical Trial Design
Modern clinical trials are increasingly adopting patient-centered approaches to address operational challenges and improve study participation.
Key strategies include:
- Decentralized or hybrid trial models that reduce travel and logistical barriers for patients
- Digital symptom tracking and wearable devices that capture real-time patient-reported outcomes
- Flexible scheduling and patient engagement initiatives that support adherence and retention
By integrating these strategies with non-invasive diagnostic approaches, researchers can reduce patient burden while generating higher-quality, real-world data.
Collaboration and the Path Forward
Progress in endometriosis research depends on collaboration across pharmaceutical companies, biotechnology innovators, clinical research organizations, and healthcare providers. Shared expertise helps streamline study execution, expand access to diverse patient populations, and accelerate the development of new therapies.
Advances in non-invasive diagnostics, innovative treatments, and patient-centered clinical trial designs have the potential to shorten diagnostic delays, improve treatment outcomes, and enhance quality of life for millions of patients worldwide.
Endometriosis Awareness Month serves as a reminder of the continued need for innovation, collaboration, and patient-focused research. By addressing study challenges and prioritizing patient experience, the clinical research community can transform trials into powerful tools for meaningful progress.